ReviewEuropean heart journal open2026
Outcomes of catheter ablation for ventr tachycardia in structural heart disease: a meta-analysis and quality appraisal of trials.
Review in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiopulmonary Support During Catheter Ablation of Ventricular Arrhythmias: Long-Term Results from a Single-Center Experience.Journal of cardiovascular development and disease · 2026Article
- The VISTA Scores: Development and Internal Validation of Novel Clinical Models for Predicting Recurrence and Mortality After Ventricular Tachycardia Ablation.Diagnostics (Basel, Switzerland) · 2026Article
- Is age still a barrier in ventricular tachycardia ablation? A study of safety, efficacy and clinical outcomes in the elderly.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Catheter ablation (CA) of ventricular tachycardia (VT) in patients with structural heart disease is usually reserved for those with recurrent implantable cardioverter defibrillator (ICD) shocks or intolerant to anti-arrhythmic drugs. This meta-analysis synthesizes available trial evidence on CA for VT to clarify the role of this approach. Methods and results: MEDLINE, PubMed, EMBASE and Cochrane were searched for randomized controlled trials (RCTs) of patients with structural heart disease allocated to receive either CA or standard treatment. Outcomes of interest were: all-cause and cardiovascular (CV) mortality, VT recurrence, incidence of appropriate ICD therapy, CV hospitalizations and VT storm. Evidence was appraised using the risk of bias tool and the grading of recommendations assessment, development and evaluation (GRADE) approach. Trial-level pairwise meta-analyses were conducted for all outcomes. Reconstructed time-to-event data meta-analysis was also performed for all-cause mortality 13 RCTs ( Conclusion: A potential all-cause mortality reduction by catheter ablation requires further confirmation in a properly powered RCT. No reduction in cardiovascular mortality was found. VT recurrence, CV hospitalizations, VT storm and ICD therapy were all significantly reduced by catheter ablation in patients with structural heart disease. Lay summary: We examined the effectiveness of catheter ablation (CA) for treating ventricular tachycardia (VT) in patients with structural heart disease, particularly those facing recurrent implantable cardioverter defibrillator shocks or unable to tolerate medications by analysing several randomized controlled trials. The findings suggest that while CA may not significantly reduce overall mortality, it can lead to fewer recurrences of VT and hospitalizations related to cardiovascular problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.